Kornimate/medical-research-clean huggingface dataset:
evaluation of deltoid exercises on injection site pain after (bnt162b2) covid - 19 vaccination

Conditions: Vaccines, Adverse Effects; Injection Site Reaction

Summary: pfizer - biontech (bnt162b2) covid - 19 vaccine is the first vaccine to be approved for emergency use by fda. the most commonly reported side effect of the bnt162b2 vaccination is mild-to-moderate pain at injection site, i.e. deltoid muscle. injection site pain may be observed during and after vaccine injection, and severity of pain may vary according to the type of vaccine, patients age, sex, level of anxiety, needle size, injection site and technique and patient positioning. vaccination pain is one of the reasons of vaccine hesitancy and world health organization (who) recommended various measures to mitigate pain at the time of vaccination. exercise is one of the suggested methods to relieve the pain and anxiety in various conditions including vaccination site pain. however, we found no studies addressing injection site pain after the vaccination and pain associated with bnt162b2 vaccine. aim of our study is to evaluate effectiveness of deltoid muscle exercises to relieve injection site pain observed after bnt162b2 vaccination.

the study was started at the designated covid - 19 vaccination department of bursa yuksek ihtisas research and training hospital approvals was obtained from republic of turkey ministry of health and institutional review board and ethics committee and the study was conducted in concordance with declaration of helsinki. volunteers were selected among the healthy persons who admitted to our vaccination department to have bnt162b2 vaccine. selection criteria were age being over 18, having no physical disability to perform the physical exercises given and willingness to participate in the study and sign an informed consent. people under the age of 18, patients with conditions that prevent them doing the exercises given and who did not want to participate in the study were excluded from the study. volunteers who accept to participate in the study, were randomized in to exercise vs. no-exercise groups according to a previously formed online randomization list. all volunteer's demographic data and vaccination status (first or second dose) were recorded. both groups were asked to keep a five - day pain diary using numeric rating scale (nrs) and to also record any use of analgesics, any hospital admissions, any side effects other than injection site and arm pain and the time of cessation of pain.

Eligibility criteria:
inclusion criteria: * vaccination with bnt162b2 * having no physical disability to perform the physical exercises given * willingness to participate in the study and sign the informed consent form exclusion criteria: * vaccination with vaccines other than bnt162b2 * having physical disability to perform the physical exercises given * not willing to participate in the study and sign the informed consent form

Keywords: bnt162b2 exercise injection site reaction pain management
titration study to evaluate efficacy and satisfaction of viagra in men with erectile function.

Conditions: Impotence

Summary: to evaluate the efficacy of viagra dose titration to 100mg versus 50mg in men with erectile dysfunction, based on responses to the iief questionnaire as measured at the beginning and at the end of double blind treatment, comparing the group titrated to 100mg vs. the group maintained on 50mg.


Eligibility criteria:
inclusion criteria: * documented clinical diagnosis of ed by using iief-ef domain with score of â‰¤ 25. * subjects must be in a stable relationship with the same partner for at least 6 months and willing to attempt sexual intercourse. exclusion criteria: * subjects in whom sexual activity is inadvisable in the opinion of the investigator such as significant cardiovascular disease in the last 6 months; including cardiac failure, myocardial infarction, unstable angina, stroke or transient ischemic attack (tia), symptomatic or clinically significant cardiac arrhythmias including atrial fibrillation. * subjects who are currently taking or are likely to be treated with nitrates or nitric oxide donors in any form (oral, sublingual, buccal, transdermal, inhalational or as aerosols) on either regular or intermittent basis.
imaging of brain amyloid plaques in the aging population

Conditions: Alzheimer's Disease; Dementia With Lewy Bodies; Frontotemporal Dementia; Vascular Dementia

Summary: this is a prospective, open label, non-therapeutic, diagnostic imaging study. the purpose of this study is to utilize pittsburgh compound b positron emission imaging (pib pet) to ascertain the relationship between change in amyloid burden over time, and concurrent change in clinical status.

identification of risk factors and biomarkers of neurodegenerative disease is essential in caring for the growing numbers of elderly. imaging biomarkers provide non-invasive ways to look at brain function. a new pet imaging agent, pittsburgh compound b (pib), that identifies brain amyloid is an exciting development in brain imaging that needs to be studied. we plan to study this imaging technique in normal volunteers and patients with a variety of neurodegenerative diseases to determine its utility. long term followup of these subjects will allow us to understand the predictive ability of this new test.

Eligibility criteria:
inclusion criteria: * age 30-100 * subjects who have completed or are scheduled to undergo the neurological evaluation procedures in the mayo clinic study of aging, mayo adrc, or mayo neurodegenerative disease clinics. exclusion criteria: * subjects unable to lie down without moving for 10 minutes * women who are pregnant or cannot stop breast feeding for 24 hours at the time of scanning * claustrophobic patients unable to tolerate the scans * standard safety exclusionary criteria for mri such as metallic foreign bodies, pacemaker, etc.

Keywords: imaging pet pib fdg mci dementia alzheimer's disease brain amyloid
fructose consumption and metabolic dysregulation

Conditions: Central Obesity; Hypertriglyceridemia

Summary: high fructose intake is increasingly recognized as causative in development of prediabetes, metabolic syndrome and cardiovascular disease (cvd). the mechanisms underlying fructose-induced metabolic disturbances are unclear but are beginning to be unraveled. in contrast to metabolism of glucose, the breakdown of fructose leads to the generation of metabolites that stimulate hepatic de novo lipogenesis (dnl) and increased levels of both fasting and postprandial triglycerides. the key lipogenic transcription factor seems to be activated by fructose independently of insulin. however, it is still controversial whether fructose consumption increases dnl in man to the extent that it induces metabolic disturbances. animal studies have shown that also the adipose tissue is responsive to fructose feeding fructose, and that high fructose-feeding induces insulin resistance and inflammation in the adipose tissue. the role of intestinal insulin resistance in fructose-induced dysmetabolism has not been studied in detail. the critical question is whether the metabolic disturbances are induced by calorie excess or by fructose per se.

detailed description: study subjects will participate to studies 1-4 before and 3 m after fructose diet: 1. an oral fat load or a kinetic study with stable isotopes combined with an oral fat load. 2. determination of liver, subcutaneous and intra-abdominal fat. (proton magnetic resonance spectroscopy ) 3. lipolytic enzymes, advanced lipid analysis, fat biopsies and genetic studies and gut microbiota profiling 4. oral glucose tolerance test and analysis of incretins and inflammatory biomarkers.

Eligibility criteria:
inclusion criteria: * body mass index 27-40 * waist \> 96 cm * age 20-60 years * male exclusion criteria: * smoking * active health problems * contraindications to mri scanning * bleeding tendency * abnormal liver or renal function tests * type 2 diabetes * evidence of metabolic or viral liver disease * alcohol intake \> 21 units per week * chronic medication except ones needed for stable hypertension

Keywords: fructose hypertriglyceridemia postprandial lipids de novo lipogenesis stable isotopes
lidocaine usage for pupil dilatation (mydriasis)

Conditions: Cataract

Summary: the purpose of this study is to determine if the mydriatic effect of intracameral lidocaine 1% is as effective as topical cyclopentolate 1% and phenylephrine 10% for achieving effective mydriasis during phacoemulsification surgery.

former studied done on the effect of intracameral lidocaine 1% compared to topical mydriatic agents for achieving effective mydriasis during phacoemulsification surgery have compared 2 different groups of patients, ie; one group received topical agents and the other received intracameral lidocaine. the resultant pupil size was recorded and evaluated in the 2 groups. our purpose is to compare the effect of these agents on the same group of people. patients recruited will be invited first for evaluation at least 1 week before the surgery. during this evaluation 1 dose (drop) of topical cyclopentolate 1% and phenylephrine 10% will be instilled to the evaluated eye 3 times at 10 minutes intervals. after 1 hour from the last instillation pupil diameter will be recorded. in the second part of this study during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds. the resultant values will be evaluated/compared.

Eligibility criteria:
inclusion criteria: * cataract * men and women * can read and sign informed consent form exclusion criteria: * sensitivity to lidocaine * sensitivity to ephrine * any other ocular surgeries * diseases like adie's pupil, horner syndrome

Keywords: cataract mydriasis lidocaine
vitamin d supplementation in systemic lupus erythematosus

Conditions: Vitamin D Deficiency

Summary: systemic lupus erythematosus (sle) is a systemic autoimmune disorder. it mainly involves the skin, the joints, the nervous system and the kidney and may be life threatening. sle is associated with production of autoantibodies and perturbations in regulatory t cells and t helper lymphocytes producing interleukin (il)-17 (th17 cells). treatments include corticosteroids, hydroxychloroquine and immunosuppressive agents. immunomodulatory effects of vitamin d supplementation in vitro was recently described, notably the expansion of treg able to suppress inflammatory responses mediated by cd4+ and cd8+ t cells and the decrease of th17 cells.

systemic lupus erythematosus (sle) is a systemic autoimmune disorder. it mainly involves the skin, the joints, the nervous system and the kidney and may be life threatening. sle is associated with production of autoantibodies and perturbations in regulatory t cells and t helper lymphocytes producing interleukin (il)-17 (th17 cells). treatments include corticosteroids, hydroxychloroquine and immunosuppressive agents. immunomodulatory effects of vitamin d supplementation in vitro was recently described, notably the expansion of treg able to suppress inflammatory responses mediated by cd4+ and cd8+ t cells and the decrease of th17 cells. objective : to evaluate the cellular immune response after vitamin d supplementation in patients with sle. methods : this is an open prospective trial. sle patients with hypovitaminosis d (\< 30 ng/ml) receive vitamin d supplementation. 100 000 ui of cholecalciferol per week for 4 weeks then 100 000 ui of cholecalciferol per month for 6 months will be administered. all patients are followed after the beginning of vitamin d supplementation at month 2 and month 6. end points : 1. clinical and biological tolerance: absence of hypercalcemia or lithiasis during and after vitamin d supplementation. 2. immunologic follow-up of t cells and b cells homeostasis (including treg and th17) and gene expression profile in pbmcs using transcriptomic analysis, before, during and after vitamin d supplementation. 3. clinical efficacy: follow-up of clinical manifestations of sle and disease activity score (sledai) during and after vitamin d supplementation. schedule : duration of patients' inclusion period is estimated 3

Eligibility criteria:
inclusion criteria: * systemic lupus erythematosus * age \> 18 years * serum vitamin d levels \[25(oh)d\] \< 30 ng/ml * low to moderate active disease without modification of associated treatments exclusion criteria: * pregnancy * serum 25(oh)d levels \> 30 ng/ml * flare requiring modification of treatments

Keywords: systemic lupus erythematosus vitamin d supplementation regulatory t cells th17 cells
the novel electrolyzed water spray treatment the genital itching

Conditions: Genital Inflammation; Itching

Summary: the purpose of this study is to test whether spraying the genitalia of patients by use of the novel electrolyzed water spray will produce improvement in the condition of genitalia itching.

in this study, water inculding tap water,pure water and salt water, and an apparatus for producing electrolyzed water (https://www.deposon.com.cn; https://www.deposon.com）were used to generate an electrolyzed water mist spray or spray. this instantly generated electrolyzed water mist spray or spray has oxidation-reduction potential (orp) ≥1200mv,and contains non-specific total oxidation capacity which equals to 0.28±0.10ppm,0.06±0.04ppm and 3.92±0.39ppm of desolved ozone. this instantly generated electrolyzed water mist spray or spray does not release detectable ≥0.1mg/m3 of gaseous ozone. this instantly generated electrolyzed water mist spray or spray has ph 8.4±0.4 and releases negative air ion.the apparatus for producing electrolyzed water has a positive electrode which is covered by a conductive diamond material (patent# cn215308550u). this is an open-label, single-arm, and before and after treatment comparison study. this study uses this novel electrolyzed water device and the water spray to treat genital itching.

Eligibility criteria:
inclusion criteria: patients with genital itching. exclusion criteria: severe genital itching. 80 years or older.

Keywords: electrolyzed water device hydroxyl radical tap water spray genital itching
efficacy and safety study of cd07805/47 topical gel in subjects with facial erythema associated with rosacea

Conditions: Rosacea

Summary: the purpose of this vehicle controlled study is to evaluate the efficacy and safety of cd07805/47 gel 0.5% applied topically once daily (qd) for 4 weeks, and cd07805/47 gel 0.18% applied topically once daily (qd) or twice daily (bid) for 4 weeks, in subjects with moderate to severe facial erythema associated with rosacea.


Eligibility criteria:
inclusion criteria: * male or female, who is at least 18 years of age or older. * a clinical diagnosis of rosacea. * a clinician erythema assessment (cea) score of 3 at screening and at pre-dose (t0) on baseline/day 1. * a patient self assessment-5 (psa-5) score of 3 at screening and at pre-dose (t0) on baseline/day 1. * a patient self assessment-11 (psa-11) score of 5 at screening and at pre-dose (t0) on baseline/day 1. exclusion criteria: * three (3) or more facial inflammatory lesions. * current diagnosis of raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, sjögren's syndrome, or depression. * known allergies or sensitivities to any components of the study medications, including the active gel ingredient, brimonidine tartrate. * intraocular pressure (iop) measurement less than 10 mm hg.
postoperative changes in optic nerve sheath diameter in patients undergoing spinal anesthesia for cesarean delivery

Conditions: Intracranial Hypotension

Summary: this is observational study. the investigator will measure optic nerve sheath diameter by ultrasound on the eye after cesarean section under spinal anesthesia.


Eligibility criteria:
inclusion criteria: * patients undergoing cesarean section under spinal anesthesia exclusion criteria: * patients who did not agree to participate in the study * patients has ophthalmic diseases * patients has previous history of ophthalmic surgery. * patients has neurological disorders. * patients has history of head surgery.
efficacy of the brand-name latanoprost and one of its generic version in primary open angle glaucoma and ocular hypertension

Conditions: Primary Open Angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to evaluate and compare efficacy and tolerability of the brand-name latanoprost and one of its generic version in subjects with primary open angle glaucoma or ocular hypertension. this randomized, double-blinded, cross-over design study has a 4 months follow-up. there are two periods of 8 weeks. during the first period, subjects put brand-name latanoprost in one eye and the generic version in the other one. in the second period, drops are switched from one eye to the other. there are intraocular pressure measurements (diurnal curves) on day 0 (before treatment), at 8 weeks (at the end of first period) and at 16 weeks (at the end of second period). variations of intraocular pressure in each eye will be evaluated.


Eligibility criteria:
inclusion criteria: 1. \>18 years old 2. primary open angle glaucoma, glaucoma suspect or ocular hypertension 3. bilateral 4. without any treatment or treated with latanoprost or another prostaglandin analog 5. intraocular pressure \>21mmhg (without treatment or after a washout period) exclusion criteria: 1. intraocular pressure \>30mmhg 2. secondary glaucoma (uveitic, neovascular, traumatic ) or congenital glaucoma 3. pseudoexfoliation syndrome 4. pigmentary dispersion syndrome or pigmentary glaucoma 5. severe glaucoma; cup-to-disc ratio ≥9/10 ou loss of central visual field (central 10°) 6. use of other topical medication to lower intraocular pressure 7. pregnancy and breast-feeding 8. being allergic to latanoprost or benzalkonium chloride (bak) 9. current use of acetazolamide (diamox) 10. changes of systemic doses of beta-blockers during study 11. recent use of topical corticosteroids (\<1 month) 12. contact lens wearer 13. closed angle at gonioscopy or past angle closure glaucoma 14. filtration surgery (example. : trabeculectomy) 15. selective laser trabeculoplasty (slt) or argon laser trabeculoplasty(alt) 16. recent intraocular surgery (\<3 months) 17. refractive surgery 18. recent iridotomy or capsulotomy (\<3 months) 19. past medical history of ocular trauma (example : angle recession) 20. past or active uveitis 21. herpetic keratitis 22. monocular vision

Keywords: primary open angle glaucoma ocular hypertension latanoprost generic intraocular pressure
identify prognostic biomarkers of lung cancer

Conditions: Lung Cancer; Lung Adenocarcinoma; Lung Squamous Cell Carcinoma; Non Small Cell Lung Cancer

Summary: multi-omics and clinical data analysis is potential to predict the prognosis of lung cancer patients.

lung cancer is the leading cause of cancer-related death in china. in order to improve prognosis of lung cancer as well as provide new therapeutic targets, the identification of effective biomarkers for the prognosis of lung cancer is of great significance. it has been reported that some small molecules such as lncrna, circrna and polypeptides in human plasm have good prospects in diagnosing or evaluating the stage of diseases. in this study, we planned to use multi-omics combined with clinical data to discovery some small molecules that are potential to predict the prognosis of lung cancer patients. in addition, we want to construct a new risk score model that provide a candidate model for prognostic evaluation of lung cancer. and we hope our study can provide insights for precision immunotherapy of lung cancer by exploring the differences in clinical characteristics, tumor mutation burden, and tumor immune cell infiltration between different risk score groups.

Eligibility criteria:
inclusion criteria: * patients diagnosed with lung cancer; * untreated lung cancer patients; * no history of chronic or serious diseases, such as cardiovascular disease, liver disease, kidney disease, respiratory disease, blood disease, lymphatic disease, endocrine disease, immune disease, mental disease, neuromuscular disease, gastrointestinal system disease, etc. exclusion criteria: * patients with other tumors; * lung cancer patients who had been treated; * abnormal liver and kidney function; * acute and chronic infectious diseases
evaluation of the marginal integrity of recent bulk fill flowable composite vs glass ionomer for carious cervical restorations: rcct

Conditions: Dental Caries Class v

Summary: the study will be conducted to assess the marginal integrity of different types of restorations (ketac ™ n100 - ketac™ universal and bulk fill flowable composite) in class v restoration using usphs criteria.


Eligibility criteria:
inclusion criteria: 1. presence of at least one carious buccal cervical lesion. 2. the absence of tooth mobility. 3. presence of contact with opposite teeth without any abnormal occlusion stress for the selected teeth. 4. accessible isolation and observable and easily accessible gingival margins during tooth restoration. exclusion criteria: 1. patients with poor oral hygiene. 2. the presence of any para functional habit. 3. abnormal occlusion. 4. any regurgitation problem. 5. subjects with compromised medical history. 6. pulpitis, non-vital or endodontically treated teeth.
infrapyloric and greater curvature lymph node metastasis in colon cancer

Conditions: Colorectal Neoplasm

Summary: the infrapyloric (no.206) and greater curvature (no.204) lymph node metastasis in adenocarcinoma located at hepatic flexure and right half of transverse colon has not been well discribed and analysed. the aim of this study is to assess the rate of this lymph node metastasis and to reveal its prognostic value for colon cancer located at hepatic flexure and right half of transverse colon. meanwhile, we can evaluate the safety and feasibility of this extented lymphadenectomy in right hemi-colectomy.


Eligibility criteria:
inclusion criteria: * age between 18 and 75 years * american society of anesthesiologists (asa) score i to iii * a biopsy proven histological diagnosis of colorectal carcinoma * tumor located at hepatic flexure and right half of transverse colon * undergoing right hemi-colectomy with extented lymphadenectomy of infrapyloric (no.206) and greater curvature (no.204) lymph node * preoperative staging ct2-4an0m0 or ctanyn+m0 * willing to participate and informed consent signed exclusion criteria: * pregnant or lactating women * synchronous colorectal carcinoma * history of colorectal cancer or other malignant tumors * clinical evidence of metastasis * preoperative staging ct1n0 or ct4bnany * emergency procedure

Keywords: colon adenocarcinoma lymph node metastasis right hemi-colectomy